HMM304 - Therapeutic Development

Year:

2021 unit information

Enrolment modes: Trimester 2: Burwood (Melbourne), Waurn Ponds (Geelong)
Credit point(s): 1
EFTSL value: 0.125
Prerequisite:

HMM202 or SLE212

Corequisite:

Nil

Incompatible with:

Nil

Study commitment

Students will on average spend 150 hours over the teaching period undertaking the teaching, learning and assessment activities for this unit.

Scheduled learning activities - campus

1 x 2 hour class per week and 1 x 1 hour (equivalent) online class per week and 1 x 1 hour seminar per week

Content

This unit describes how therapeutics such as pharmacological drugs are discovered and developed, in order to treat disease. Non-targeted and targeted drug discovery is discussed, in addition to target validation, in the contexts of big pharmaceutical companies and smaller research laboratories. Drug development strategies and pipelines that are adopted by big pharmaceutical companies are then described, including the chemical optimisation of lead compounds, pre-clinical and clinical trials, commercialisation and post-market considerations.

Unit Fee Information

Click on the fee link below which describes you:

Talk to a Deakin adviser about studying at Deakin today

Call 1800 693 888Monday to Friday: 9am to 5pm AEST
Chat live nowMonday to Thursday: 8am to 7pm AEST
Friday: 9am to 5pm AEST